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Objective: Primary sarcomas involving the chest wall requiring full-thick-
ness excision are rare. We reviewed our experience with these lesions in a
tertiary referral cancer center by using multidisciplinary approaches.
Methods: A 10-year retrospective study identified 51 patients referred with
primary sarcomas of the chest wall: 40 for initial treatment and 11 after pre-
vious unsuccessful surgical excisions elsewhere (secondary referral).
Presenting symptoms were pain alone in 23 (45%) of 51 patients, pain with
an associated mass in 8 (16%) patients, and an asymptomatic mass alone in
13 (25%) patients. Median symptom duration was 241 days in the primary
group and 225 days in the recurrent group. Tumor locations were the ster-
num (n = 11), the rib alone (n = 36), and the posterior rib with extension into
vertebral bodies (n = 4). Histologic types included the following: chon-
drosarcomas (n = 15), malignant fibrous histiocytomas (n = 9), osteosarco-
mas (n = 4), Ewing sarcomas (n = 3), desmoid tumors (n = 7), and other
types (n = 13). The median tumor volume of those referred initially was 311
cm3 compared with 84 cm3 in patients with recurrent lesions.
Results: Twenty-six (51%) of 51 patients received treatment before resection,
including chemotherapy alone (n = 22), radiation alone (n = 3), and com-
bined chemotherapy and radiation therapy (n = 1). The complete sternum
was removed in 6 of 11 patients, and the average number of ribs requiring
resection was 3.8. Four patients had vertebral body resections. Prosthetic
meshes alone were required in 16 of 51 patients, and meshes with methyl-
methacrylate were required in 18 of 51 patients. Muscle flap reconstructions
by plastic surgery were required in 24 patients. Negative margins were
obtained in 47 of 51 patients. There were no perioperative deaths with mor-
bidities occurring in 12 (24%) of 51 patients (wound [n = 3], prolonged air
leak [n = 1], prolonged ventilator requirement [n = 1], arrhythmias [n = 3],
doxorubicin (Adriamycin)-induced cardiomyopathy [n = 1], and other [n =
3]). Postoperative treatment was administered to 13 patients (chemotherapy
alone, n = 9; chemotherapy with radiation therapy, n = 4). The cumulative 5-
year survival of all patients was 64% (initial referral, 61.3%; secondary
referral, 72.7%). The average follow-up is 44.7 months.
Conclusions: A combined aggressive multidisciplinary approach to primary
sarcomas of the chest wall resulted in no treatment-related deaths and a
cumulative 5-year survival of 64% in patients referred to our tertiary care
cancer center.  (J Thorac Cardiovasc Surg 2001;121:48-60)
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P rimary sarcomas that involve the chest wall arerare.1,2 These tumors originate either in the bone or
cartilage of the thoracic skeleton or in the surrounding
soft tissues with direct invasion into the interspace or
bone. Osias Aimar, in 1778, is believed to have per-
formed the first resection of a chest wall tumor.
Parham, over a century ago in 1899, was the first to
resect a chest wall sarcoma by means of positive-pres-
sure endotracheal ventilation.3 Before this, breaching
the integrity of the pleural envelope would result in an
immediate ipsilateral pneumothorax and would often
prove fatal to the patient. Many advances in oncology,
anesthesia, and surgical procedure have improved the
operative morbidity and mortality and long-term sur-
vival of these patients. Most series in the world litera-
ture, however, are small and usually extend over sever-
al decades with a variety of approaches to these lesions.
We wished to review our recent experience over the
past decade with a multidisciplinary approach to bony
and soft-tissue sarcomas that involved the chest wall
that required full-thickness excision and reconstruction
at our tertiary referral cancer center.
Methods
From January 1, 1990, to December 31, 1998, a total of
1222 patients were identified who had a malignant tumor
involving their chest wall at the time of their initial referral to
The University of Texas M.D. Anderson Cancer Center
(MDACC). For this study, we defined “chest wall” as any
neoplasm involving the sternum, ribs, costovertebral junc-
tion, or vertebral body. Tumors of the scapula and clavicle
were excluded from this analysis. The vast majority of
patients had nonsarcomatous metastatic lesions to the tho-
racic skeleton. One hundred sixty-six patients had a sarcoma
histology. Eight-seven patients ultimately underwent surgical
resection of these neoplasms. Thirty-six patients had sarco-
mas that were metastatic to the chest wall, and 51 were pri-
mary chest wall sarcomas that were either of bone or soft-tis-
sue origin with invasion of the bony thorax. These 51 patients
are the focus of this article.
Forty of these 51 patients were referred initially to our ter-
tiary care center for definitive treatment of their malignant
disease. However, many had undergone some form of biopsy
before transfer. Eleven patients were secondarily referred
after previous curative surgical attempts, with local tumor
recurrence in the surgical bed.
A retrospective chart review examined the following data
elements: patient age; sex; presenting symptoms; symptom
duration; history of previous radiation therapy for another
malignancy; tumor location; tumor volume; use of excision-
al, incisional, or needle biopsies to obtain tissue; histologies;
and the use of neoadjuvant chemotherapy or radiation thera-
py before resection. Surgical techniques, morbidity and mor-
tality, pathologic margins, and the use of prosthetic and plas-
tic surgical reconstructive techniques were reviewed.
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Postoperative adjuvant therapies were identified. Patients
were followed up until March 31, 2000, and patient status
(alive or dead) and disease status (free of disease or local-dis-
tant tumor recurrence) were recorded.
Statistics. Survival was calculated for two time-dependent
end points. The first end point was overall survival, which
was defined as the time in months from the date of operation
at our institution until the date the patient was last known to
be alive. Any death from any cause was considered a failure.
Recurrence-free survival was the second time-dependent end
point. This was defined from the date of operation at
MDACC to the date of the most recent clinic follow-up visit.
A failure was defined if a documented sarcoma recurrence
occurred during this follow-up period. Two patients (both
residing outside of the United States) were excluded from the
recurrence-free survival analysis because their disease status
in regard to sarcoma recurrence was unknown at the time of
their death. For the remaining 49 patients, we have complete
follow-up data to March 2000, with a median follow-up of
44.7 months. Distributions of overall survival and recurrence-
free survival times were calculated by the Kaplan-Meier
method and compared by use of the log-rank test. Factors
analyzed for prognostic significance included the following:
type of referral (initial vs secondary referral), age
(dichotomized into patients < 50 years of age vs those ≥ 50
years of age), sex, tumor location (sternum vs rib with or
without vertebrae), symptomatic presentation (pain vs no
pain), tumor size in cubic centimeters (dichotomized into
<500 cm3 vs ≥500 cm3), tumor histology (desmoid tumors vs
chondrosarcomas vs high-grade sarcomas), number of ribs
resected (<4 vs ≥4 for tumors involving the ribs), complete
versus partial resection of the sternum (for primary sternal
lesions), extended resections requiring more than rib and
soft-tissue chest wall (ie, lung, diaphragm, pericardium, and
thymus), radiation-induced sarcomas versus other high-grade
sarcomas, margins (negative vs positive), and use of neoadju-
vant or adjuvant therapies, including chemotherapy, radiation
therapy, or both compared with patients undergoing an oper-
ation alone. A multivariate analysis of these variables was
performed by the Cox proportional hazards model. All statis-
tical analyses were performed with SPSS software (SPSS,
Inc, Chicago, Ill).
Results
Demographics. Fifty-one patients were referred to
our center with primary sarcomas involving the chest
wall from 1990 to 1998. There were 23 male and 28
female patients, with a median age of 47 years (range,
10-81 years). Presenting symptoms included pain alone
in 23 (45%) of 51 patients, pain with an associated
mass in 8 (16%) of 51 patients, and a mass alone in 13
(25%) of 51 patients. Two patients presented with
dyspnea, one with generalized fatigue, and one with a
radicular paresthesia. Three patients were completely
asymptomatic, with the lesion discovered during a rou-
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tine screening chest radiograph. The median duration
of symptoms for those in the initial referral group (40
patients) was 241 days (range, 10-3833 days), and that
of the secondary referral group (11 patients) was 225
days (range, 46-814 days) from the time they first
noticed the symptoms of their tumor recurrence until
rediagnosis. The disease-free interval of the 11 patients
(date of previous operation until diagnosis of recur-
rence made at MDACC) was 591 days (range, 138 days
to 20.1 years).
Tumor location and volume. Eleven patients had
tumors originating in the sternum. Thirty-six patients
had rib tumors only (23 anterior, 2 lateral, and 11 pos-
terior). Four patients had tumors that involved the ver-
tebral bodies, each extending over multiple levels,
including one T3-5, one T2-6, one T5-7, and one T1-5.
The median volume of tumors for the initial referrals
was 311 cm3 (range, 6-1200 cm3; Fig 1) and a some-
what smaller volume in the secondary referral group of
84 cm3 (range, 9-776 cm3). Of the 51 patients, 8
patients underwent definitive operations without an ini-
tial biopsy. Nine patients had an excisional biopsy, and
7 patients had an incisional biopsy. Twenty-seven had
the initial tissue procurement through fine-needle aspi-
ration or core needle aspiration. A definitive diagnosis
was made by our cytopathologist in 24 (89%) of 27
Fig 1. Computed tomographic images and accompanying final pathologic specimen of a grade I chondrosarcoma
involving the costal margin and lower portion of the sternum. This tumor slowly progressed over a 10-year period.
The patient presented with anterior chest discomfort and the obvious mass. Computed tomographic images demon-
strate the classic findings of a chondrosarcoma, and therefore an initial biopsy was not performed.
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patients and correlated in each case with the final sur-
gical pathology. Three patients required more tissue
after fine-needle aspiration or core needle biopsy: two
had incisional biopsies, and one underwent an exci-
sional biopsy (Fig 2).
Histologies. There were a variety of histologies both
of bone and soft-tissue origin. Overall, there were 15
chondrosarcomas, 4 osteosarcomas, 3 Ewing sarcomas,
9 malignant fibrous histiocytomas, 7 desmoid tumors,
and 13 others. These are divided up by location and
type of referral, as shown in Table I. We have included
desmoid tumors in this article because of their aggres-
sive local behavior and tendency to recur and the fact
that extensive resections are often required.4 Many
pathologists and surgical and medical oncologists truly
consider these lesions as low-grade sarcomas. We have
therefore separately analyzed the survival and recur-
rence data for desmoid tumors and chondrosarcomas
(typically a low-grade sarcoma) from the rest of the
other sarcomas in our patient population, which are of
higher grades.
Radiation-associated sarcomas. Eight patients had
received radiation therapy for a metachronous malig-
nancy, including Hodgkin lymphoma in 2 patients,
breast cancer in 4 patients, large cell carcinoma of the
lung in 1 patient, and a Wilms tumor in 1 patient. Their
sarcomas had occurred in the previous radiation portals
and included 1 spindle cell sarcoma, 2 neurogenic sar-
comas, 1 osteosarcoma, 1 malignant fibrous histiocy-
toma, 1 peripheral nerve sheath sarcoma, and 2
angiosarcomas. The median time interval from previ-
ous radiation therapy until the development of the sar-
coma was 9 years (range, 6-26 years). In the 4 patients
in whom the previous radiation dosage was known, the
average dose was 48 Gy (range, 42-60 Gy).
Use of neoadjuvant therapy. Multiple different drug
regimens and combinations were used to treat these
patients. Basic regimens used in our institution for
osteosarcoma include doxorubicin (75-90 mg/m2) and
cisplatin (120 mg/m2), high-dose methotrexate (8-12
g/m2), or standard ifosfamide (10 g/m2) or high-dose
Fig 2. Method of histologic diagnosis of sarcoma in the 51 patients. All incisional and excisional biopsies were per-
formed at outside institutions. Fine-needle aspirates (FNA) and biopsy specimens obtained with a Tru-Cut biopsy
needle (Allegiance Healthcare Corporation, McGaw Park, Ill) are the preferred methods for diagnosis at our insti-
tution. Eight patients were taken directly to the operating room without a biopsy solely on the basis of the radio-
logic appearance of the tumor.
Table I. Tumor histology
Initial Secondary 
referral referral
Rib (n = 36) and vertebrae
(n = 4); total, n = 40
Malignant fibrous histiocytoma 6 2
Ewing sarcoma 3 0
Osteosarcoma 4 0
Chondrosarcoma 3 3
Desmoid tumor 5 2
Synovial cell sarcoma 1 0
Neurogenic spindle cell sarcoma 2 0
Poorly differentiated-unclassified 
or anaplastic sarcomas 6 1
Angiosarcoma 0 2
Sternum (n = 11)
Chondrosarcoma 8 1
Malignant fibrous histiocytoma 1 0
Spindle cell sarcoma 1 0
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ifosfamide (14 g/m2). Ewing sarcomas are radiation
sensitive. Chemotherapy choices for Ewing sarcoma
include single agents proven in phase II trials, includ-
ing cyclophosphamide (50% response), doxorubicin
(40% response), ifosfamide (32%), vincristine
(30%), and etoposide (30%) with a less than 7%
response to single-agent cisplatin. Combinations of
the above (CyVADIC: cyclophosphamide, vincristine,
Adriamycin, dacarbazine [DTIC]) are often tried.
Chondrosarcomas are both radiation and chemotherapy
insensitive, although higher grade chondrosarcomas
and dedifferentiated chondrosarcomas are treated with
similar agents, as described above. For soft-tissue sar-
comas, doxorubicin is one of the most active single
agents (15%-45% response rate). Ifosfamide has a sim-
ilar response rate and is often given with doxorubicin
for a synergistic response. Advanced desmoid tumors,
which often are technically difficult to resect with clear
margins, can be treated with radiation therapy postop-
eratively. They are also hormonally responsive and
have been treated at our institution with tamoxifen.
Twenty-six of the 51 patients in this review received
some form of neoadjuvant treatment.
Chemotherapy alone. Twenty-two patients received a
variety of neoadjuvant chemotherapy regimens. The
tumor histologies included malignant fibrous histiocy-
toma in 7 patients, osteosarcomas in 4 patients, Ewing
sarcomas in 3 patients, poorly differentiated sarcomas in
3 patients, an angiosarcoma in 1 patient, desmoid tumors
in 2 patients, and chondrosarcomas in 2 patients.
Combination chemotherapy and radiation thera-
py. Combination therapy was used in 1 patient with a
monophasic spindle cell sarcoma. A low preoperative
dose of 18 Gy was used.
Radiation alone.  Radiation alone was used in 3
patients (2 patients with malignant fibrous histiocy-
tomas [50 Gy each] and 1 patient with a malignant
peripheral nerve sheath tumor [10 Gy]).
Operations
Sternum. Six total sternectomies and 5 partial
sternectomies were performed for those patients with
tumors involving the sternum. Six patients had extend-
ed resections (adjacent thoracic structures other than
chest wall and soft tissues), including 2 (18%) of 11
lung resections and 4 (36%) of 11 thymus resections.
Reconstruction involved the use of prosthetics in 10 of
the 11 patients. One patient with an isolated resection
of the manubrium had the defect closed with bilateral
rotational pectoralis major flaps without synthetic sup-
port. Mesh and methylmethacrylate were used in 9
patients, and 1 patient had Prolene mesh (Ethicon, Inc,
Somerville, NJ) only without cement.
Rib. Thirty-six patients had primary rib resections.
The average number of ribs removed was 3.8 (range, 1-
9 ribs). Twenty of the 36 patients had extended tissue
resections, including lung in 14 (39%) patients,
diaphragm in 4 (11%) patients, thymus in 1 patient, and
a forequarter amputation in 1 patient. Fourteen (39%)
of the 36 patients required Marlex (Bard Implants,
Billerica, Mass), Prolene, or polytetrafluoroethylene*
alone, and 8 (22%) of the 36 patients used mesh and
methylmethacrylate. Of the 22 patients requiring pros-
thetic reconstruction, 15 required reconstruction for
anterolateral defects and 7 for posterior defects. This
represents 60% of the anterolateral tumors and 64% of
the posterior tumors that required prosthetics.
Vertebrae. A total of 4 combined rib and vertebral
body resections were performed, with 1 patient requir-
ing vertebral body reconstruction. The 3 remaining
patients had subtotal resections of the vertebrae that
were not believed to compromise the structural stabili-
ty of the vertebral spinal column. The average number
of ribs removed in addition to the vertebral resection
was 5 (range, 3-8). Pulmonary resections were required
in 2 of the vertebral resections (50%). Only 1 of the 4
patients required prosthetic mesh reconstruction and
muscle flap coverage. The 3 remaining patients had the
defect adequately protected and covered by the scapu-
la and posterior chest wall musculature.
Plastics flaps. A total of 24 pedicled muscular or
myocutaneous flaps were used for soft-tissue coverage,
including 8 pectoralis major, 6 rectus abdominis, and 8
latissimus dorsi flaps. Eight of the 11 sternal resections
required muscle flaps (2 latissimus and 6 pectoralis
flaps). Sixteen of the 40 rib and vertebral body resec-
tions required muscle flaps (7 latissimus, 5 rectus
abdominis, 1 reverse abdominoplasty, 1 deltopectoral
flap; 1 multiple flap of the rectus, latissimus, and pec-
toralis; and 1 bilateral pectoralis advancement flap).
There were no flap failures; however, 3 partial skin-flap
dehiscences required additional wound care.
Surgical morbidity and mortality. Negative final
pathologic margins were obtained in 47 of 51 patients.
Incomplete margins occurred in 4 patients: 1 grossly
positive margin because of extensive vertebral body
involvement, 1 microscopic positive soft-tissue medi-
astinal margin during a sternal resection, and 2 rib
resections that had microscopic soft-tissue margins
positive on final pathologic review but negative during
frozen section. Additional resections could not be per-
*Gore-Tex mesh, a registered trademark of W. L. Gore & Associates,
Inc, Flagstaff, Ariz.
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formed. The 30-day perioperative mortality was zero.
The median ventilator requirement was 1 day (range, 0-
194 days). Median surgical intensive care unit stay was
2 days (range, 0-194 days).
Complications occurred in 12 (24%) of 51 patients
and included 3 arrhythmias, 1 congestive heart failure
caused by doxorubicin cardiotoxicity, and 4 respiratory
complications, including prolonged respiratory failure
in 1 patient who required transfer to a chronic rehabili-
tation facility 194 days after a complex chest wall and
vertebral body resection and bilobectomy for osteosar-
coma. There were 3 wound complications, 2 necessi-
tating subsequent removal of the prosthetic mesh.
Median hospital stay was 7 days (range, 2-194 days).
When we exclude the 1 patient with prolonged venti-
latory failure, the average ventilatory requirements of
patients with a prosthesis (n = 33) was 2.8 days com-
pared with 1.4 days for those without prostheses (n =
17; P = .325, t test). Similarly, there was no significant
difference between the group for the average surgical
intensive care unit stay (3.4 days compared with 2.1
days, P = .37) and the average length of hospital stay
(9.5 days with a prosthesis compared with 8.5 days
without a prosthesis, P = .60). For patients requiring
muscle flaps (n = 24), the average ventilator days were
3.8 days compared with 0.9 days for patients without
muscle flaps (n = 26, P = .04). The surgical intensive
care unit days were 4.4 days versus 1.6 days (P = .05).
The average hospital length of stay was 11.4 days ver-
sus 7.0 days for patients not requiring muscle flaps 
(P = .01). These statistics likely reflect the greater mag-
nitude of the operations that required prosthetics and
autologous muscle flaps.
Adjuvant therapy. Thirteen patients received addi-
tional therapy after resection, including 2 of the 4
patients with microscopic positive margins. Ten
Table IIA. Prognostic factors for overall 5-year survival
Variable Overall 5-year survival (n = 51) P value
Total population 63.7%
Type of referral (initial vs secondary) Initial (n = 40) 61.3% .87
Secondary (n = 11) 72.7%
Age (<50 vs ≥50 y) <50 (n = 28) 67.8% .47
≥50 (n = 23) 58.3%
Sex Male (n = 23) 54.4% .30
Female (n = 28) 71.3%
Tumor location (sternum vs rib ± vertebrae) Sternum (n = 11) 90.0% .08
Rib ± vertebrae (n = 40) 55.3%
Symptomatic presentation (pain vs no pain) Yes (n = 31) 65.2% .86
No (n = 20) 64.5%
Tumor size (<500 vs ≥500 cm3) <500 (n = 23) 74.6% .05
≥500 (n = 13) 40.0%
Histology (desmoid tumors vs chondrosarcomas vs high-grade sarcomas) Desmoid tumors (n = 7) 100.0% .001
Chondrosarcomas (n = 15) 90.0%
High-grade sarcomas (n = 29) 42.9%
No. of ribs resected (<4 vs ≥4) <4 (n = 20) 53.4% .65
≥4 (n = 20) 56.7%
Extent of sternal resection (complete vs partial) Complete (n = 6) 83.3% .41
Partial (n = 5) 100%
Extended resection of adjacent structures Yes (n = 24) 57.0% .24
No (n = 27) 69.9%
Radiation-induced sarcomas (radiation-induced vs other high-grade sarcoma) High grade (n = 21) 53.3% .11
Radiation-induced sarcoma (n = 8) 6.5 mo (median)
Margins (negative vs positive) Negative (n = 47) 67.2% .02
Positive (n = 4) 25.0%
Use of perioperative chemotherapy, radiation therapy, or both Yes (n = 29) 58.3% .29
No (n = 22) 70.5%
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patients received chemotherapy alone, 2 received com-
bination chemotherapy and radiation therapy, and 1
received radiation therapy alone.
Prognostic factors for survival. Univariate analyses
were performed to determine which factors influenced
overall 5-year survival and 5-year disease-free survival
(Tables IIA and IIB). The overall 5-year survival of our
patient population was 63.7% (Fig 3). Patients who
were referred for local tumor recurrence after previous
curative surgical attempts interestingly fared no worse
than those presenting for their initial treatment (Fig 4).
Recurrence of sarcomas after resection is, in most
series, known to be a poor prognosticator and is usual-
ly associated with metastatic disease. There was a ten-
dency for female patients to have improved survival.
This could not be explained through cross tabulation
analysis by age and histology of female patients com-
pared with male patients. Female patients had a ten-
dency to have a greater proportion of high-grade sarco-
mas and were of the same age as our male patients.
Patients undergoing sternal resections survived longer,
likely because of a higher proportion of chondrosarco-
mas (81% of the sternal histologies). Pain is recognized
to be a poor predictor of malignancy in patients pre-
senting with undiagnosed chest wall masses and it also
did not affect long-term survival in our patients with
proven cancer. A large tumor tended to do worse in our
patient population, although in some studies this was
not consistently demonstrated. Histology, as expected,
is the most significant predictor of survival (Fig 5).
Radiation-induced sarcomas had the worst survival of
the group but not statistically worse than that of other
Table IIB. Prognostic factors for overall recurrence-free 5-year survival
Variable Recurrence-free 5-year survival (n = 49) P value
Total population 53.5%
Type of referral (initial vs secondary) Initial (n = 38) 50.5% .85
Secondary (n = 11) 60.6%
Age (<50 vs ≥50 y) <50 (n = 27) 52.7% .60
≥50 (n = 22) 53.1%
Sex Male (n = 21) 47.9% .51
Female (n = 28) 57.9%
Tumor location (sternum vs rib ± vertebrae) Sternum (n = 11) 90.0% .04
Rib ± vertebrae (n = 38) 42.6%
Symptomatic presentation (pain vs no pain) Yes (n = 29) 41.7% .28
No (n = 20) 69.3%
Tumor size (<500 vs ≥500 cm3) <500 (n = 23) 46.7% .43
≥500 (n = 12) 20.0%
Histology (desmoid tumors vs chondrosarcomas 
vs high-grade sarcomas) Desmoid tumors (n = 7) 66.7% .002
Chondrosarcomas (n = 15) 92.3%
High-grade sarcomas (n = 27) 30.3%
No. of ribs resected (<4 vs ≥4) <4 (n = 20) 40.9% .47
≥4 (n = 18) 45.7%
Extent of sternal resection (complete vs partial) Complete (n = 6) 83.3% .41
Partial (n = 5) 100%
Extended resection of adjacent structures Yes (n = 22) 50.1% .51
No (n = 27) 56.4%
Radiation-induced sarcomas (radiation-induced 
vs other high-grade sarcoma) High-grade sarcoma (n = 21) 26.4% .20
Radiation-induced sarcomas (n = 8) 4.8 mo (median)
Margins (negative vs positive) Negative (n = 45) 56.0% .10
Positive (n = 4) 25.0%
Use of perioperative chemotherapy, radiation therapy, or both Yes (n = 29) 36.6% .05
No (n = 20) 81.4%
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high-grade sarcomas (Fig 6). The magnitude of the
resections, including complete sternums or a greater
number of ribs or extended resections that required
involved intrathoracic organs, did not significantly
affect long-term survival or predict recurrence. Our
data clearly indicate that it is the pathologic complete-
ness of resection rather than the extent of resection that
is one of the most important factors in the surgical man-
agement of these malignant tumors. Patients with posi-
tive margins (gross or microscopic) had a median sur-
vival of less than 5 months (P = .02, Fig 7).
In the recurrence-free survival analyses, 53.5% of the
patients survived without disease at 5 years. Nine
patients had locoregional recurrences, and 12 had dis-
tant recurrences. Histology was again statistically sig-
nificant at predicting recurrence (P = .002, Fig 8). This
histologic influence is reflected in tumor location as a
positive predictor of disease-free survival because the
sternal location had a higher proportion of chondrosar-
comas. Although the use of perioperative chemothera-
py or radiation therapy appears to negatively affect sur-
vival and tumor recurrence, this is likely a reflection of
the severity and grade of the sarcoma for which these
therapies are used.
Multivariate analyses were performed to identify pre-
dictors of long-term survival and long-term disease-
Fig 3. Overall 5-year survival of our patient population was
64%.
Fig 4. Overall 5-year survival for those patients initially
referred for management and those referred after previous
surgical resections with recurrence of their tumors (sec-
ondary referrals).
Fig 5. Five-year overall survival by histology.
Fig 6. Five-year overall survival of radiation-induced sarco-
mas compared with other high-grade sarcomas in our patient
population.
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free survival (Tables III and IV). The greatest predictor
of survival was histology for both overall and disease-
free survival. The risk ratio confidence interval, how-
ever, was large, reflecting the heterogeneity of our pop-
ulation.
Discussion
For the year 2000, The American Cancer Society has
estimated an incidence in the United States of 2500 pri-
mary bone tumors and approximately 8100 new cases
of soft-tissue malignant tumors. This represents 0.2%
and 0.7%, respectively, of the total expected 1,220,100
new cancer cases for all sites. The chest wall is a rare
site for primary sarcomas and represents 6% to 7% of
the total. Often, chest wall sarcomas present as slowly
growing masses that are clinically misinterpreted as
benign, which results in a long delay in diagnosis.5 We
have seen, in our patient population, delays in diagno-
sis of over 10 years from the initial discovery of a mass.
Although these lesions are rare, they can represent, in
children under 15 years of age, one of the top five
malignant tumors responsible for cancer deaths.6
Because of their rarity and lethality, referral to a ter-
tiary referral center with a multidisciplinary approach
to these malignant tumors is usually of paramount
importance.
A plain chest radiograph, posteroanterior, and lateral
radiograph with focused rib or sternal views are initially
performed. Lesions are examined for lytic and blastic
components and for any associated periosteal reaction. A
computed tomographic review of the chest is mandatory,
with special attention to bone views. The computed
tomographic scan permits assessment of both the
extrathoracic and intrathoracic tumor extension, as well
as the direct extension into the lung, diaphragm, thymus,
or pericardium and is usually sufficient for resectional
planning of most tumors. Magnetic resonance imaging
evaluations are useful in assessing lesions involving the
costovertebral junction and vertebral body proper, and
permit a detailed evaluation of involvement of the verte-
bral bodies, disc space, and extension through the neural
foramina toward the dural sac.
Consultation with a bone radiologist is often impor-
tant. Many lesions, especially cartilaginous tumors, can
be reliably diagnosed by their radiographic presenta-
tion alone, obviating the need for any biopsy. If the
Fig 7. Overall 5-year survival by final pathology margin sta-
tus.
Fig 8. Overall disease-free 5-year survival by histology.
Table III. Multivariate analysis of overall survival
Variable Risk ratio Confidence interval P value
Tumor location 2.1 0.23–18.7 .51
Histology 23.0 2.1–251.9 .01
Margins 3.7 0.90–15.6 .07
Sex 2.8 0.90–8.4 .08
Age 2.0 0.70–5.7 .19
Radiation-induced sarcoma 2.0 0.59–6.9 .26
Perioperative chemotherapy ± radiation therapy 2.4 0.59–10.2 .22
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diagnosis is still in question, two treatment options are
possible. First, if the lesion is less than 2 to 3 cm in size
involving one rib, then an excisional biopsy can be the
next step. If a malignant neoplasm is diagnosed, then a
wider excision can be performed. A minimum of a 2-
cm margin is required for low-grade tumors, and a 4-
cm margin with a rib above and below the tumor is
required for high-grade sarcomas.
For large tumors of borderline resectability or a
lesion that is suspected of being a sarcoma that is
known to respond to neoadjuvant therapy (Ewing sar-
coma, osteosarcoma, or malignant fibrous histiocy-
toma), then a preoperative histologic assessment is
required. Many clinicians typically advocate perform-
ing a well-placed incisional biopsy, planned in such a
manner to minimize tumor spillage, avoiding he-
matomas and sewing up the capsule of the tumor and
obtaining at least 1 cm3 of tissue. We have found, how-
ever, that skilled cytopathologists, through the use of
fine-needle aspirations or trephine core needle biopsies,
can make a diagnosis in nearly 90% of our patients.7
Even if the exact subtyping of the tumor is not possible,
sufficient material can usually be obtained to guide pre-
operative chemotherapy or radiation therapy planning.
The volume of tissue required to make a diagnosis is
often inversely related to the experience of the patholo-
gist in dealing with sarcomas.8 As a tertiary referral
center, we often have to contend with many complica-
tions in the management of both chest wall sarcomas
and extremity sarcomas from incisional biopsies that
were either not needed, ill placed, or poorly performed,
resulting in local tissue tumor contamination. What
may have been a relatively straightforward chest wall
resection may now require a greater sacrifice of bone
and soft tissues, necessitating prosthetic stabilization
and plastic reconstruction.
Therefore, our general approach is to avoid incision-
al and excisional biopsies and proceed initially to fine-
needle aspiration or core needle biopsy or directly to
the formal planned operation if the radiographic diag-
nosis is clear. We have not performed an incisional
biopsy of a chest wall lesion for nearly 15 years at our
hospital.9,10 If a preoperative histologic diagnosis is
made, those lesions that have known responses to
chemotherapy are usually treated for 2 to 3 cycles with
up-front chemotherapy. This permits an in vivo assess-
ment of chemosensitivity, theoretically treats occult
metastasis at a subclinical and subradiologic stage, and
may facilitate future surgical dissections and the abili-
ty to obtain clean surgical margins if the tumor shrinks
with treatment. Because chest wall sarcomas are rare,
many of the treatment strategies have been extrapolat-
ed from experience with extremity sarcomas and
applied to the chest wall lesions. Although similar
chemotherapy and radiation sensitivity is frequently
noted, this is not always the case.
Surgical planning requires a team approach that
always includes a thoracic surgeon and thoracic anesthe-
siologist and may involve plastic surgeons or spine sur-
geons for lesions requiring extensive soft-tissue resec-
tion or vertebral body or dural sac involvement. Wide
excision with clear margins is the most important prog-
nosticator for long-term survival. Most structures in
proximity to the chest wall and sternum can be sacrificed
and reconstructed if necessary.11 Surgical morbidity and
mortality in our series and those of others are low.12-15
Virtually all chest wall defects can be stabilized and
reconstructed if sufficient preoperative planning is
done.16 Although many chest wall defects that are pro-
tected by the scapula and posterior musculature do not
require reconstruction, lateral chest wall and sternal
defects require reconstruction for protection of the
underlying viscera, improvement in respiratory
mechanics that can significantly shorten ventilator
requirements, and overall hospital stay and mainte-
nance of the thorax shape for an improved cosmetic
result.17 Wide margins remain the most important sur-
gical objectives when treating these patients. The abla-
tive surgeon must never compromise his or her resec-
tion because of a concern for closing the defect.18 A
separate plastic surgery team must focus on this aspect
of the patient’s care.
Table IV.  Multivariate analysis of recurrence-free 5-year survival
Variable Risk ratio Confidence interval P value
Tumor location 2.3 0.25-21.3 .46
Histology 26.4 2.2-321.9 .01
Margins 3.3 0.79-14.1 .10
Sex 2.8 0.53-15.2 .23
Age 2.8 0.90-8.6 .08
Radiation-induced sarcoma 2.2 0.68-7.0 .19
Perioperative chemotherapy ± radiation therapy 1.9 0.55-6.78 .30
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Although the exact role of chemotherapy for the
management of these lesions is less well defined than
for extremity sarcomas, every effort should be made to
consider these patients for combined modality therapy
to improve local control and prevent the development
of metastatic disease that ultimately is responsible for
the death of many of our patients.19,20
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Discussion
Dr Mark S. Allen (Rochester, Minn). The authors have
nicely presented their series of patients, which is fairly typi-
cal of what a tertiary referral center would see. The wide vari-
ety of pathologic cell types and different presentations make
me cautious when I try to generalize any conclusions from
the data. The distribution of the cell type is fairly typical with
what others have reported at other major institutions in that
chondrosarcoma is most common, with malignant fibrous
histiocytoma and desmoid tumors seen less often. The
authors also show that almost half their patients received
some sort of preoperative therapy, and a smaller, although
still significant, number received postoperative chemotherapy
and radiation therapy. It is also of interest that approximately
two thirds of their patients received some sort of artificial
material for reconstruction, and approximately one half of the
patients received some type of muscle flap for reconstruction.
I compliment the authors on their use of the multiple team
to take care of these patients. Despite all of these large oper-
ations, their mortality rate was zero, and they had a compli-
cation rate of only 24%, with wound problems being the most
common. The overall survival of 64% is a little bit difficult to
interpret because of the different cell types.
I have several questions for the authors. First, I would like
to ask Dr Walsh to expound on the preoperative evaluation. It
is unclear to me exactly what type of biopsy is required
before the initiation of chemotherapy or radiation therapy. In
your article you state that you always use a needle biopsy. I
was taught as a resident to use a properly placed incisional or
excisional biopsy to get adequate tissue to obtain a proper
diagnosis. Is this approach outdated now? Do I have to do
something different with my cytopathologists or my patholo-
gists to get them to read the needle biopsy results correctly?
I think this information would be helpful to pass along, not
only for the members of our Association but for other prima-
ry care doctors who may see these patients and may read this
article in our Journal.
What margin did you try to achieve at the time of your sur-
gical resection? In the report from the Mayo Clinic by
McAfee and associates in 1985, we found a very good suc-
cess rate when we enlarged our margins to 4 cm from the
tumor in the case of a chondrosarcoma, which led to a cure
rate of almost 97%. When the margins were less than that, the
cure rates were not as good. In your article you state that
complete resection is the goal rather than the margin of resec-
tion. What do you believe we should tell people and our res-
idents about this? There seems to be some confusion in the
operating room when the residents say, “Well, I heard we
should take a rib above and a rib below,” or they have some
absolute distance from the tumor that we should try to strive
for. Can you shed some insight into this question and into
what we should use as an acceptable margin?
Finally, do you use any molecular markers or genetic mark-
ers to help you decide what kind of preoperative or postoper-
ative therapy to give these patients? What does this new
The morbidity of the more extended resections is low.
Long-term survival, as we have both demonstrated, is often
predicated on the surgeon’s ability to obtain clear margins.
Frozen section, soft tissue margins are performed intraopera-
tively. We would accept a 2- to 3-cm margin for lower-grade
tumors.
As far as genetic markers, to date we have not used them to
guide perioperative chemotherapies but would anticipate that
specific sarcoma genetic markers will play a vital role in
selecting patients who are to receive neoadjuvant or adjuvant
therapies in the near future as we learn more about the prog-
nostic significance of these markers.
Dr Altorki, univariate analysis did not demonstrate an
improved 5-year survival when chemotherapy and/or radia-
tion therapy was used. The 5-year recurrence-free survival
was, in fact, worse. The two groups, however, are not compa-
rable as chemotherapy was generally reserved for patients
with higher-grade sarcomas. Chemotherapy is used for two
purposes. One is to deal with the lesion itself in an effort to
shrink it down to make the resection perhaps technically eas-
ier to obtain clear margins. The second is to treat subclinical,
micrometastatic disease that often results in the death of the
patient years later. In patients with limb osteosarcoma and
Ewing sarcomas, we have seen the dramatic improvement in
survival when chemotherapy is employed. We have applied
this important management strategy to patients with chest
wall sarcomas. 
As far as the extent of resection, we will try again to look at
the preoperative CT scans and try to resect back to the initial
radiographic presentation of the lesion. Frozen section analysis
in the operating room is used to guide the extent of resection.
As far as vertebral body resections, we have had an extensive
combined experience with our neurosurgeons at M.D.
Anderson with over 300 patients requiring anterior vertebral
body resections and reconstructions for a variety of primary
and metastatic tumors involving the spinal column. In the
patient population of this study, 1 patient required a complete
vertebrectomy with reconstruction and the 3 others required
only partial vertebrectomy with formal spinal stabilization.
Dr Anderson, the median ventilator requirement for the 6
patients in our study who had total sternectomies was 3 days
as compared with 1 day for the 5 patients with partial sternal
resections. This was not a significant difference. In a previous
report from our institution reviewing our experience from
1984 to 1990 with Marlex mesh used in chest wall resections
for a wide variety of chest wall pathologies, we noticed a sig-
nificant decrease in the ventilator requirements and hospital
length of stay when the defect was supported with prosthet-
ics without any increased risk of wound infection. In this
report pertaining to chest wall sarcomas only, there was no
significant difference in ventilator requirements, intensive
care, or hospital lengths of stay. Patients who required mus-
cle flaps, however, had significantly longer ventilator require-
ments and intensive care unit and hospital stays in this patient
population.
Dr Miller, as far as the high-grade sarcomas, we present all
of these more complex cases at our weekly joint Thoracic
Surgery/Sarcoma multidisciplinary conference to discuss treat-
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world of molecular biology have in store for us in the future
to help us care for our patients?
Dr Nasser Altorki (New York, NY). I have 3 questions for
you. Can you comment on the response rate to the preopera-
tive chemotherapy? How do you deal with the margin or the
extent of the resection in tumors that have significantly
shrunk like the one you showed? Is that based on the
prechemotherapy size? Finally, would you expound a bit
more on those tumors that are in close proximity to the verte-
bral bodies? How were those managed?
Dr Timothy M. Anderson (Buffalo, NY). I noticed that you
had 6 patients who underwent complete sternal resections, yet
you only commented on 1 patient with prolonged ventilatory
dependency. In a previous study at Emory University (Ann
Thorac Surg 1993;55:838-43), Mansour and associates
showed complete resection as opposed to a partial resection
as causing a longer time until extubation. Can you comment
on whether complete sternal resection resulted in a longer
ventilation time?
Dr Joseph I. Miller, Jr (Atlanta, Ga). I would like to ask
you 1 question from the moderator’s standpoint. In your
group of high-grade sarcomas, if a patient comes in tomorrow
and you choose to administer preoperative neoadjuvant ther-
apy, how many cycles of chemotherapy would you give pre-
operatively, what drugs would you use, and would you add
radiation to that patient in the group with primary high-grade
sarcoma of the chest wall?
Dr Peter Goldstraw (London, England). I am intrigued by
desmoid tumors because my general surgical colleagues tell
me that they get a very high success rate with complete exci-
sion of abdominal desmoid tumors and very good long-term
results. Like you, I get good clearance of desmoid tumors.
They do not die, but they keep recurring. They keep coming
back for 5 and 10 years and have a very protracted and mis-
erable life course. Negative margins do not seem to have any
effect on the recurrence rate. Have you found anything that
you can do to improve the results with thoracic desmoid
tumors?
Dr Walsh. I would like to thank all of the discussers for
their excellent questions and will respond in order. 
First, Dr Allen, after reviewing our recent experience, I feel
the use of incisional biopsies in the evaluation of chest wall
masses should be abandoned. This is one of the major points
that we wish to emphasize with this paper. Incisional biopsies
can significantly compromise a future en bloc, oncologic
resection and reconstruction of the resulting chest wall defect.
A preoperative consultation with a bone radiologist and the
selective use of fine needle or trephine biopsies interpreted by
a skilled cytopathologist should be adequate to plan future
treatment options. Low-grade, cartilaginous lesions can be
resected solely on the basis of their radiographic appearance,
without the need even for needle biopsies.
In regard to margins, we concur with the published reports
from your center and we would strive to obtain at least a 4-
cm chest wall margin for high-grade tumors and would resect
en bloc any contiguous structure that is clinically involved,
including the vertebral body, lung, diaphragm, thymus, or
pericardium.
ment options. Our sarcoma medical oncologists would usually
administer 2 or more cycles of chemotherapy, and the timing of
surgery would be based on the ongoing response of the lesion.
Over 25 different drug regimens were used in this study. Many
of the combinations were chosen on the basis of our experience
with similar tumor histologies, often at other tumor locations.
The final question from Dr Goldstraw regarding desmoid
tumors—our experience would be more in line with yours
than with your general surgical colleagues. These are very
difficult tumors to control long term and, as such, we felt they
warranted inclusion in this manuscript on chest wall sarco-
mas. I feel, as many of our pathologists do, that they are low-
grade sarcomas because of their invasiveness into structures
and the difficulty that they pose for us as thoracic surgeons.
Interestingly, they are radiation-sensitive, so the margins
can be improved through the use of radiation therapy. We
have also seen some fairly dramatic responses in some large,
technically unresectable desmoids to combination doxoru-
bicin and dacarbazine chemotherapy. We have also seen
responses to low-dose methotrexate and vinblastine. These
tumors are also hormonally sensitive and can respond both
radiographically and symptomatically to tamoxifen.
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